SCHEMBL1373241

CC[C@H](C)[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)[C@@H](C)CC)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)O)[C@@H](C)O

nearest known ligand 0.67

Predicted protein targets (top 6)

	gene	UniProt	supporting neighbours	confidence
▸	GLP1R	P43220	17/20	0.67

▸	ECE1	P42892	1/20	0.61

▸	MUS81	Q96NY9	1/20	0.61

▸	NPBWR1	P48145	2/20	0.58

▸	PTH1R	Q03431	1/20	0.58

▸	CCKBR	P32239	1/20	0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL3356603	0.95	GLP1R (0.67)	GLP1RECE1MUS81NPBWR1CCKBR
SCHEMBL29943233	0.90	GLP1R (0.79)	GLP1RECE1MUS81CCKBR
SCHEMBL30167097	0.89	GLP1R (0.62)	GLP1RECE1MUS81
SCHEMBL30607427	0.89	GLP1R (0.68)	GLP1RECE1MUS81
SCHEMBL31099254	0.89	GLP1R (0.78)	GLP1RECE1MUS81CCKBR
SCHEMBL30432138	0.89	GLP1R (0.68)	GLP1RECE1MUS81NPBWR1
SCHEMBL30431337	0.89	GLP1R (0.70)	GLP1RECE1MUS81NPBWR1PTH1R
SCHEMBL38650746	0.89	GLP1R (0.65)	GLP1RECE1MUS81NPBWR1
SCHEMBL30906493	0.88	GLP1R (0.70)	GLP1RECE1MUS81NPBWR1CCKBR
SCHEMBL30906486	0.88	GLP1R (0.70)	GLP1RECE1MUS81NPBWR1CCKBR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20110288011-A1	PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF	ANGIOCHEM INC. (CA)	2011-11-24	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20110288011-A1	PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF	VIP, SLC1A5, SLC47A1	GLP1R 56/4885ECE1 677/4885MUS81 4285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.